EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations

Elodie Long-Mira iD, Christophe Bontoux iD, Guylène Rignol, Véronique Hofman iD, Sandra Lassalle iD, Jonathan Benzaquen iD, Jacques Boutros iD, Salomé Lalvée-Moret, Katia Zahaf, Virginie Lespinet-Fabre, Olivier Bordone, Sophia Maistre und 7 weitere

Cancers · 20.03.2025 · 17 (6) · 1034

DOI: 10.3390/cancers17061034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.03.2025. Verfasst von Elodie Long-Mira und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical and Experimental Pathology, IHU RespirERA, Biobank Côte d'Azur BB-0033-00025, FHU OncoAge, Centre Hospitalier Universitaire de…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, FHU oncoage.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immune checkpoint inhibitors (ICIs) benefit some lung cancer patients, but their efficacy is limited in advanced lung adenocarcinoma (LUAD) with EGFR mutations (EGFRm), largely due to a non-immunogenic tumour microenvironment (TME). Furthermore, EGFRm LUAD patients often experience increased toxicity with ICIs. CD73, an ectonucleotidase involved in adenosine production, promotes tumour immune evasion and could represent a novel therapeutic target. This study investigates CD73 expression in LUAD with EGFR alterations and its clinico-pathological correlations.

Methods

CD73 expression in tumour (CD73TC) and stromal (CD73SC) cells was assessed in 76 treatment-naive LUAD patients using immunohistochemistry (IHC) (D7F9A clone) alongside IHC PD-L1 (22C3 clone). EGFR alterations were identified by molecular sequencing and FISH. Event-free survival (EFS) was analysed based on CD73TC expression.

Results

CD73TC expression was observed in 66% of cases, with high expression (Tumour Proportion Score > 50%) correlating with improved EFS (p = 0.045). CD73TC and PD-L1 expression were not significantly correlated (p = 0.44), although a weak inverse trend was observed. CD73SC expression was detected in 18% of cases, predominantly in early-stage (p = 0.037), PD-L1-negative (p = 0.030), and non-EGFR-amplified (p = 0.0018) tumours. No significant associations were found with disease stage, histological subtype, EGFR mutation type, and amplification.

Conclusions

CD73 expression in EGFRm LUAD is heterogeneous and associated with diverse TME profiles. These findings support the potential of CD73 as a predictive biomarker and therapeutic target, highlighting its clinical relevance in EGFRm LUAD.

Schlagwörter

Stichwörter der Autor:innen

CD73EGFRPD-L1immunohistochemistryimmunotherapylung adenocarcinomanon-small cell lung cancer

Autor:innen und Institutionen

  • Laboratory of Clinical and Experimental Pathology, IHU RespirERA, Biobank Côte d'Azur BB-0033-00025, FHU OncoAge, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.
  • Institute for Research on Cancer and Aging, Team 4, Inserm U1081, CNRS UMR 7413, Université Côte d'Azur, 06000 Nice, France.
  • Department of Thoracic Oncology, IHU RespirERA Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, 06100 Nice, France.
  • Department of Thoracic Surgery, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, 06100 Nice, France.

ORCID-Profile: Elodie Long-Mira, Christophe Bontoux, Véronique Hofman, Sandra Lassalle, Jonathan Benzaquen, Jacques Boutros, Charles-Hugo Marquette, Marius Ilié, Paul Hofman

Förderung

  • Agence Nationale de la Recherche
  • FHU oncoage

Zitieren

APA

Long-Mira, E., Bontoux, C., Rignol, G., Hofman, V., Lassalle, S., Benzaquen, J., Boutros, J., Lalvée-Moret, S., Zahaf, K., Lespinet-Fabre, V., Bordone, O., Maistre, S., Bonnetaud, C., Cohen, C., Berthet, J. P., Marquette, C. H., Vouret-Craviari, V., Ilié, M., & Hofman, P. (2025). Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations. Cancers, 17(6), 1034. https://doi.org/10.3390/cancers17061034

Vancouver

Long-Mira E, Bontoux C, Rignol G, Hofman V, Lassalle S, Benzaquen J, et al. Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations. Cancers. 2025;17(6):1034. doi:10.3390/cancers17061034

BibTeX
@article{LongMira2025,
  author = {Long-Mira, Elodie and Bontoux, Christophe and Rignol, Guylène and Hofman, Véronique and Lassalle, Sandra and Benzaquen, Jonathan and Boutros, Jacques and Lalvée-Moret, Salomé and Zahaf, Katia and Lespinet-Fabre, Virginie and Bordone, Olivier and Maistre, Sophia and Bonnetaud, Christelle and Cohen, Charlotte and Berthet, Jean-Philippe and Marquette, Charles-Hugo and Vouret-Craviari, Valerie and Ilié, Marius and Hofman, Paul},
  title = {Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {1034},
  doi = {10.3390/cancers17061034}
}
Kostenlos starten →